BioCryst Pharmaceuticals, Inc. / Estimates

    Fiscal Year Revenue Net income Net margin Free cash flow FCF margin
    (estimated) €751.29M +8.9% €236.31M +21.9% 31.5% +0.033 pp N/A N/A
    (estimated) €689.97M +10.1% €193.91M +35.3% 28.1% +0.052 pp N/A N/A
    (estimated) €626.85M +10.9% €143.30M +31.0% 22.9% +0.035 pp €212.55M +9.3% 33.9% -0.0050 pp
    (estimated) €565.21M +5.9% €109.42M +492.5% 19.4% +0.16 pp €194.47M +52.0% 34.4% +0.10 pp
    (estimated) €533.85M +38.9% €18.47M -124.4% 3.5% +0.23 pp €127.94M -394.7% 24.0% +0.35 pp
    €384.44M +36.0% -€75.81M -60.8% -19.7% +0.49 pp -€43.41M -45.3% -11.3% +0.17 pp
    €282.68M +22.4% -€193.23M -8.3% -68.4% +0.23 pp -€79.30M -42.1% -28.1% +0.31 pp
    €231.00M +72.3% -€210.78M +34.3% -91.2% +0.26 pp -€136.90M +14.8% -59.3% +0.30 pp
    €134.06M +782.4% -€157.00M +0.7% -117.1% +9.1 pp -€119.22M +2.2% -88.9% +6.8 pp
    €15.19M -63.5% -€155.93M +52.3% -1,026.4% -7.8 pp -€116.60M +53.2% -767.5% -5.8 pp
    €41.65M +136.5% -€102.41M +18.6% -245.9% +2.4 pp -€76.12M -3.2% -182.7% +2.6 pp
    €17.62M -18.0% -€86.36M +53.9% -490.3% -2.3 pp -€78.64M +125.9% -446.4% -2.8 pp
    €21.48M -4.4% -€56.11M +19.3% -261.2% -0.52 pp -€34.81M -15.3% -162.1% +0.21 pp
    €22.48M -45.4% -€47.04M +28.2% -209.3% -1.2 pp -€41.08M +502.5% -182.8% -1.7 pp
    €41.16M +254.6% -€36.69M -4.8% -89.1% +2.4 pp -€6.82M -79.2% -16.6% +2.7 pp
    €11.61M -21.5% -€38.54M +50.1% -332.1% -1.6 pp -€32.79M +45.1% -282.5% -1.3 pp
    €14.78M -34.1% -€25.68M -23.0% -173.7% -0.25 pp -€22.60M -28.9% -152.9% -0.11 pp
    €22.43M +33.9% -€33.33M -31.4% -148.6% +1.4 pp -€31.80M +15.8% -141.8% +0.22 pp
    €16.75M -69.1% -€48.57M +74.0% -289.9% -2.4 pp -€27.46M +14.1% -163.9% -1.2 pp
    €54.16M -14.9% -€27.92M +143.3% -51.5% -0.34 pp -€24.08M +80.8% -44.5% -0.24 pp
    €63.62M +31.9% -€11.47M -45.6% -18.0% +0.26 pp -€13.32M -20.6% -20.9% +0.14 pp
    €48.24M -20.6% -€21.09M -14.9% -43.7% -0.029 pp -€16.77M -99.4% -34.8% +47 pp
    €60.76M +1,046.8% -€24.78M -33.4% -40.8% +6.6 pp -€2.87B +24,532.0% -4,729.0% -45 pp
    €5.30M +3,990.4% -€37.20M +67.1% -702.2% +160 pp -€11.67M -40.1% -220.2% +150 pp
    €129.54K -54.9% -€22.26M +23.7% -17,185.3% -110 pp -€19.49M +27.8% -15,045.3% -97 pp
    €287.36K -79.4% -€18.00M +66.2% -6,264.2% -55 pp -€15.25M +60.4% -5,305.8% -46 pp
    €1.39M -7.9% -€10.83M -25.0% -777.2% +1.8 pp -€9.51M -30.2% -682.0% +2.2 pp
    €1.51M -84.1% -€14.44M +239.5% -954.0% -9.1 pp -€13.61M +111.2% -899.2% -8.3 pp
    €9.52M +236.5% -€4.25M -56.9% -44.7% +3.0 pp -€6.44M +1,562.6% -67.7% -0.54 pp
    €2.83M +32.6% -€9.88M +118.4% -349.2% -1.4 pp -€387.53K -88.4% -13.7% +1.4 pp
    €2.13M -60.9% -€4.52M +10.4% -212.0% -1.4 pp -€3.33M +2.6% -156.0% -0.97 pp
    €5.46M +540.0% -€4.09M -54.7% -75.0% +9.9 pp -€3.24M -58.7% -59.4% +8.6 pp
    €852.95K -63.0% -€9.04M +37.7% -1,060.0% -7.7 pp -€7.85M +41.5% -920.0% -6.8 pp
    €2.30M +1,250.0% -€6.57M -10.5% -285.2% +40 pp -€5.54M -13.3% -240.7% +35 pp
    €170.59K -71.4% -€7.34M +24.6% -4,300.0% -33 pp -€6.40M +23.0% -3,750.0% -29 pp
    €597.07K -€5.89M -985.7% -€5.20M -871.4%

    Notifications